Research
Original data & PubMed-cited science on GLP-1 weight loss.
We track every major GLP-1 telehealth provider in the United States and publish two kinds of long-form pieces: data investigations using our live dataset, and PubMed-cited scientific deep-dives on the studies that actually matter. Both update as the underlying data changes.
Research formats
Related tools
- Scientific deep-dive9 min · 3 sources
Ozempic Muscle Cramps: Electrolytes, Dehydration, and What Helps
Muscle cramps on a GLP-1 are not a labeled direct drug effect — the evidence points to secondary causes: dehydration, electrolyte losses from GI symptoms, and reduced food intake. Here is the clinical reasoning and what helps.
Read the analysis→ - Scientific deep-dive8 min · 4 sources
First Signs Ozempic Is Working: Early Indicators a GLP-1 Is Taking Effect
The first signs Ozempic is working appear within 1–2 weeks even at the starting dose: reduced food noise, earlier satiety, and smaller portions that feel genuinely satisfying. But meaningful weight loss builds over months as the dose titrates up — the STEP 1 trial showed 14.9% average loss over 68 weeks. Absence of nausea does not mean the drug is not working. This guide explains which early signals matter, what to expect at week 4/8/12, how to track progress beyond just the scale, and when a plateau warrants a conversation with your prescriber.
Read the analysis→ - Scientific deep-dive9 min · 4 sources
Ozempic Legs: Loose Skin, Muscle Loss, and Leg Changes Explained
"Ozempic legs" is the viral term for how rapid GLP-1 weight loss can change the appearance of the legs: fat loss thins the leg profile and makes veins more visible, lean-mass loss (a quarter to two-fifths of total weight lost is fat-free mass) reduces muscle volume and tone, and loose skin follows large, rapid fat loss that outpaces the skin's ability to contract. It is cosmetic, not dangerous. This guide covers who is most affected (rapid loss, older age, low pre-existing muscle), the two most evidence-backed prevention strategies (resistance training + protein 1.2-1.6 g/kg/day), when to consider a body contouring procedure, and why the metabolic benefits of the weight loss far outweigh the appearance changes for most patients.
Read the analysis→ - Scientific deep-dive10 min · 8 sources
ESG Results and Before-and-After: The Realistic Weight-Loss Timeline
Searching "ESG before and after" really means asking what will happen to your weight, and when. The honest answer from the trials: weight loss is fast in the early months, reaches about 13.6% total body weight loss at one year in the pivotal MERIT randomized trial, pools to roughly 15-17% across studies, and holds near 16% at five years - real fat loss that persists, not a water-weight blip. About 77% of ESG patients reached at least 25% excess weight loss in MERIT, versus 12% of controls, putting ESG roughly on par with semaglutide (~14.9%) and below tirzepatide (~20.9%). But the after is not automatic: results vary by starting weight, adherence, and follow-up, and regain is possible if the eating changes lapse. This article walks the month-by-month timeline, explains what a real before-and-after reflects, why results differ, and how combining ESG with a GLP-1 shapes the trajectory.
Read the analysis→ - Scientific deep-dive10 min · 8 sources
How Much Does a Gastric Balloon Cost? The Out-of-Pocket Price and Value
A gastric balloon in the US typically costs about $6,000-$9,000, and it is almost always paid entirely out of pocket because most insurers classify the device as investigational. That price buys a temporary 6-month device - the balloon is placed, left in for roughly half a year, then removed - after which meaningful regain is common, so the honest measure is cost per durably kept-off pound, where the balloon is the weakest value of the mainstream options. It delivers only ~11-13% total body weight loss at its peak, less than ESG (which lasts years) and less than a GLP-1, and it carries a genuine FDA safety signal including death reports. This review breaks down what the package price includes, why insurance almost never pays, how financing works, and why the 6-month cap plus regain make the value case hard to defend.
Read the analysis→ - Scientific deep-dive9 min · 7 sources
Is Endoscopic Sleeve Gastroplasty (ESG) Reversible? What the Evidence Says
Yes - ESG is generally reversible, and the reason is anatomy: it shrinks the stomach with sutures, whereas a surgical sleeve gastrectomy permanently removes 70-80% of it. Because ESG removes no tissue, the stitches can loosen, be removed endoscopically, or be revised, the procedure can be redone, and a full surgical sleeve or bypass stays completely available later. That's a sharp contrast with surgery, which cannot be undone. But the nuance most articles miss: reversible does not mean temporary. While the sutures are intact the effect is durable - about 13.6% total body weight loss at one year in the randomized MERIT trial and near 15.9% still holding at five years. A GLP-1 is reversible in a different sense - you can stop the injection, but the weight loss reverses too - whereas ESG's effect persists by default and undoing it is an active choice. This guide explains exactly what reversibility means for ESG, how it differs from surgery and from a GLP-1, and why that flexibility is one of ESG's defining advantages.
Read the analysis→ - Scientific deep-dive9 min · 6 sources
How Much Does ESG Cost? Endoscopic Sleeve Gastroplasty Price vs a GLP-1
ESG usually costs roughly $8,000-$20,000 in the United States, and you will almost always pay it out of pocket - most insurers still classify it as investigational, unlike surgical bariatric procedures they often cover. Those are current US market ranges, not trial numbers. The real question isn't whether that's a lot; it's how one large one-time payment with no recurring drug bill compares, over several years, with a GLP-1 like Wegovy or Zepbound that may be partly insured but costs money every month indefinitely. ESG's value case rests on durable weight loss - 13.6% at one year in the MERIT trial, near 16% at five years - that you buy once. If a GLP-1 nets you ~$400/month, that's ~$24,000 over five years, so a one-time $12,000 ESG can be cheaper over that horizon; if your drug is heavily subsidized or you only need it briefly, the GLP-1 may win. This guide covers what's in the price, why insurance says no, financing, and how to run the multi-year math.
Read the analysis→ - Scientific deep-dive11 min · 7 sources
ESG vs Gastric Sleeve: Incisionless Stitching vs Surgical Sleeve Gastrectomy
ESG and surgical sleeve gastrectomy share a name and a shape but not a procedure. ESG stitches the stomach smaller from the inside through the mouth and removes nothing - incisionless, outpatient, potentially reversible, about 13.6% total body weight loss at one year in the MERIT randomized trial and near 16% at five years. The surgical sleeve is an operation that permanently cuts away 70-80% of the stomach for roughly 25-30% weight loss held for a decade, but with higher procedural risk and a hospital stay. There is no head-to-head trial, so comparisons are cross-trial and directional. A GLP-1 like semaglutide lands near ESG (~14.9%) by a non-invasive route. The money math flips the medical math: the surgical sleeve is often insured while ESG is usually out of pocket. This review covers efficacy, durability, safety, reversibility, cost, and who each one suits - including how to sequence drug, ESG, and surgery.
Read the analysis→ - Scientific deep-dive12 min · 6 sources
ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence
Two very different ways to lose roughly the same weight: a one-time incisionless procedure or a weekly injection you take indefinitely. Endoscopic sleeve gastroplasty (ESG) stitches the stomach into a narrow tube and produced 13.6% total body weight loss at one year in the randomized MERIT trial - pooled around 15-17% and holding near 15.9% at five years. A GLP-1 works the other way: semaglutide delivered -14.9% in STEP-1, tirzepatide -20.9% in SURMOUNT-1 - but only while you keep injecting. There is no head-to-head randomized trial, so this is an honest cross-trial comparison across efficacy, durability, cost over time, invasiveness and risk, who each suits, and the combination approach (ESG plus a GLP-1 beat ESG alone) that can outperform either route by itself. No false winner - just the framework to decide.
Read the analysis→ - Scientific deep-dive10 min · 7 sources
Gastric Balloon vs GLP-1: Which Wins on Weight Loss, Durability, and Safety?
Should you get an intragastric (gastric) balloon or take a GLP-1 like Wegovy or Zepbound? There is no head-to-head trial, so this is a cross-trial comparison - but the answer is clear. A balloon is a one-time device left in for about 6 months, delivering roughly 7-15% total body weight loss that peaks near 11-13% and then partly reverses after removal. A GLP-1 is an ongoing medication delivering a larger, sustained-while-taking loss - about 14.9% with semaglutide and 20.9% with tirzepatide. The balloon also carries a documented FDA safety signal, including 18 death reports worldwide (8 in the U.S.), gastric perforation, acute pancreatitis, and spontaneous hyperinflation, that a GLP-1 does not require in the same form. Both improve metabolic markers, but the drug's durability and outcome evidence are stronger. The honest verdict: for most people a GLP-1 - or ESG (~13.6%, lasting years) if you want a durable procedure - is the stronger option, and the balloon's real niche is a short-term jump-start.
Read the analysis→ - Scientific deep-dive11 min · 7 sources
Gastric Balloon for Weight Loss: The Evidence vs GLP-1s, ESG, and Surgery
An intragastric balloon (Orbera, ReShape, Obalon, Spatz) is a soft silicone balloon placed in the stomach for about 6 months so you feel full on less food, then removed. In the pooled data behind FDA approval it produced roughly 25.4% excess weight loss and ~11.3% total body weight loss at 12 months, peaking near 13.2% at 6 months while the balloon is in place, across 17 studies and 1,683 patients - and it improved glucose, waist circumference, and blood pressure. But it is the least durable and generally lowest-magnitude option: below semaglutide (~14.9%), well below tirzepatide (~20.9%), and below ESG (~13.6%), with meaningful regain after removal. It also carries a real FDA safety signal - four Letters to Health Care Providers (2017-2020), 18 death reports worldwide including 8 in the U.S., plus gastric perforation, acute pancreatitis, and spontaneous hyperinflation. Usually paid out of pocket at ~$6,000-$9,000, its honest niche is a short-term jump-start. This review covers the devices, how much and how long it works, the full safety history, cost, and who it suits.
Read the analysis→ - Scientific deep-dive12 min · 9 sources
Endoscopic (Non-Surgical) Weight-Loss Options: ESG, Balloon, and GLP-1 Compared
Endoscopic bariatric therapy - weight-loss procedures done through the mouth with no incisions - has become the middle ground between a GLP-1 injection and full surgery. The two best-evidenced options are endoscopic sleeve gastroplasty (ESG), which stitches the stomach into a narrow tube (13.6% total body weight loss at one year in the randomized MERIT trial, near 16% at five years), and the intragastric balloon, a six-month device (~7-15% TBWL, with regain common after removal). Against Wegovy or Zepbound the honest read is: ESG rivals semaglutide (~14.9%), trails tirzepatide (~20.9%), and sits well below sleeve gastrectomy or bypass (~25-30%). This pillar overview maps how the endoscopic options compare to each other, to GLP-1 drugs, and to surgery on weight loss, durability, invasiveness, reversibility, and cost - with links to the ESG and balloon deep dives, and the combination approach that can beat either route alone.
Read the analysis→ - Scientific deep-dive12 min · 12 sources
Endoscopic Sleeve Gastroplasty (ESG): The Evidence vs GLP-1s and Surgery
Endoscopic sleeve gastroplasty (ESG, or 'ESG stomach tightening') is an incisionless procedure that stitches the stomach into a narrow tube through the mouth, no surgery required. Anyone weighing it against Wegovy or Zepbound wants one number: the MERIT randomized trial found 13.6% total body weight loss at one year versus 0.8% for lifestyle alone, and five-year data hold near 16%. That puts ESG roughly on par with semaglutide, below tirzepatide, and well below sleeve gastrectomy or bypass (~25-30%). Its defining advantage over a GLP-1 is being a one-time, no-injection, potentially reversible intervention with no monthly drug cost; its drawbacks are that it is invasive, usually paid out of pocket, and backed by less long-term outcome data than surgery. Serious complications run about 2% with no deaths in the major series, and ESG can be combined with a GLP-1 for more weight loss. This review covers how it works, how much and how long it works, the drug and surgery comparisons, risks, cost, reversibility, and who it suits.
Read the analysis→ - Scientific deep-dive10 min · 12 sources
Tirzepatide (Mounjaro/Zepbound), Testosterone & Male Fertility
Tirzepatide (Mounjaro for diabetes, Zepbound for weight) is the dual GIP/GLP-1 agonist that produces the largest approved weight loss - about 20.9% in SURMOUNT-1, versus 14.9% for semaglutide. Because obesity-associated low testosterone reverses in proportion to weight lost, the expected direction for an obese man is testosterone up, not down - and plausibly up by more than on semaglutide, though this has never been measured head-to-head with a testosterone endpoint. The article covers the Mounjaro context (diabetic hypogonadism is very common), the Zepbound weight-management context, whether tirzepatide directly suppresses the HPG axis, the male-fertility angle honestly, and combining TRT with tirzepatide.
Read the analysis→ - Scientific deep-dive9 min · 12 sources
Saxenda & Victoza (Liraglutide) and Erectile Dysfunction: The Evidence
Obesity and type 2 diabetes are two of the strongest modifiable causes of erectile dysfunction, working through the same lesion - endothelial dysfunction of the vascular penis. The good news: it is largely reversible with weight loss, as the Esposito 2004 JAMA trial showed by restoring erectile function in about a third of obese men through diet and exercise. Where does liraglutide fit? Saxenda and Victoza are the older, once-daily GLP-1, producing less weight loss than the newer drugs - about 8% in SCALE Obesity versus ~15% for semaglutide and ~21% for tirzepatide. That lands near the Esposito lifestyle magnitude, so a real but modest ED benefit is reasonable to expect, with a bonus: liraglutide is the one GLP-1 with its own direct, positive erectile-function data in hypogonadal men. This review walks the mechanism, the evidence, PDE5-inhibitor safety, and when weight loss is the wrong tool.
Read the analysis→ - Scientific deep-dive9 min · 13 sources
Saxenda & Victoza (Liraglutide) and Sex Drive: The Honest Evidence
Will Saxenda or Victoza raise your sex drive, or flatten it? No randomized trial of liraglutide has ever measured sexual desire as an endpoint, in men or women. But liraglutide reshapes the framing: it is the older, once-daily GLP-1, and it produces less weight loss than the newer drugs - about 8% in SCALE Obesity versus roughly 15% for Wegovy and 21% for Zepbound. Because libido changes run through weight loss and, in men, testosterone, a smaller lever means a real but more modest effect, bought with a daily injection. This review covers both sexes: the direct liraglutide-in-men signal, the testosterone chain, the PCOS-androgen wrinkle in women, and the early-nausea dip that a once-daily schedule spreads across the whole day.
Read the analysis→ - Scientific deep-dive9 min · 15 sources
'Mounjaro Penis' Explained: Diabetes, Buried Penis & Erectile Dysfunction
Diabetic men start with the worst buried penis, vascular ED, and low testosterone - Mounjaro improves glucose and weight together, attacking two drivers at once without acting on the organ. This review separates the optics of the un-burying buried penis from the physiology of improved erectile function and testosterone recovery, notes the neurogenic-ED ceiling, and flags when to see a urologist.
Read the analysis→ - Scientific deep-dive9 min · 15 sources
'Zepbound Penis' Explained: The Largest Weight Loss Un-Buries the Most Shaft
As the largest-loss agent, Zepbound un-buries more shaft and lifts testosterone more than any semaglutide brand - a fat-loss story, not a penile drug effect. This review separates the optics of the un-burying buried penis of obesity from the real physiology of improved erectile function and rising testosterone, and flags when to see a urologist.
Read the analysis→ - Scientific deep-dive9 min · 15 sources
'Wegovy Penis' Explained: Un-Burying, Better Erections & Rising Testosterone
Wegovy's larger weight loss makes the suprapubic fat-pad un-burying and the testosterone rise the most pronounced of any semaglutide brand - none of it a drug acting on the penis. This review separates the optics (the buried penis of obesity un-burying as the fat pad shrinks) from the physiology (reversing obesity-driven endothelial dysfunction and rising testosterone), addresses the side-effect rumor honestly, and flags when the right move is a urologist rather than a weight-loss drug.
Read the analysis→ - Scientific deep-dive10 min · 11 sources
Mounjaro and Erectile Dysfunction in Type 2 Diabetes: The Dual-Driver Case
Erectile dysfunction is one of the most common and most under-discussed complications of type 2 diabetes, because chronic hyperglycemia damages exactly the small vessels and autonomic nerves an erection depends on. That is what makes Mounjaro interesting: as tirzepatide, it improves the two biggest reversible drivers of diabetic ED at once - it lowers blood glucose and drives large weight loss. This article covers why diabetic ED is so prevalent, why Mounjaro is aimed at the reversible drivers, the weight-loss-to-erection evidence, the testosterone dividend in the hypogonadal diabetic man, realistic expectations given the neuropathic ceiling, PDE5-inhibitor compatibility, and when metabolic control is not enough. No tirzepatide trial measured erections, so the benefit is inferred.
Read the analysis→ - Scientific deep-dive10 min · 11 sources
Zepbound and Erectile Dysfunction: The Biggest Weight-Loss Lever for ED?
If erectile function improves in proportion to how much weight you lose - and across the published evidence it largely does - then Zepbound is the most powerful weight-loss lever an obese man with ED can pull short of surgery. Zepbound is tirzepatide, a dual GIP/GLP-1 receptor agonist whose SURMOUNT-1 trial produced 20.9% body-weight loss, the largest of any approved anti-obesity medication and well above semaglutide (STEP-1 -14.9%) and the Esposito 2004 lifestyle intervention that reversed ED in about 31% of obese men. This deep dive covers the dual-incretin mechanism, why more weight loss makes bigger erectile benefit plausible but not proven, the vascular and testosterone chain obesity damages, where Zepbound lands on the dose-response, the testosterone dividend, PDE5-inhibitor compatibility, and when weight loss is the wrong tool.
Read the analysis→ - Scientific deep-dive10 min · 11 sources
Wegovy and Erectile Dysfunction: Will Losing Weight Improve Your Erections?
The question most men ask about Wegovy and erections is simple: if I lose the weight, will I get harder erections back? In obesity-driven ED, meaningful weight loss reliably improves erectile function, and Wegovy (semaglutide 2.4 mg) is the semaglutide product built to produce the most weight loss - STEP-1 delivered 14.9% body-weight loss, more than the lifestyle weight loss that restored erectile function in about 31% of obese men in the Esposito 2004 JAMA RCT. This article walks the vascular and testosterone mechanisms by which obesity causes ED, the weight-loss-to-erection evidence, where Wegovy's weight loss lands versus Ozempic and tirzepatide, the testosterone dividend, why Wegovy does not cause ED, timing expectations, PDE5-inhibitor compatibility, and when weight loss is the wrong tool. No semaglutide trial has used an erectile-function endpoint, so the case is inference from a well-established chain.
Read the analysis→ - Scientific deep-dive10 min · 14 sources
Zepbound (Tirzepatide) and Sex Drive in Women: The Evidence
Zepbound is the tirzepatide brand approved for weight management (Mounjaro is the same molecule for diabetes) and the largest-weight-loss option on the market — SURMOUNT-1 showed about -20.9% body weight versus Wegovy's -14.9%. Since weight loss reliably improves female sexual function (FSFI) across the obesity, bariatric, and lifestyle literature, Zepbound's indirect benefit to desire, arousal, lubrication, and satisfaction may be the most pronounced of any brand - but no randomized trial has ever measured female sexual desire as an endpoint for Zepbound, tirzepatide, or any GLP-1/GIP drug. This review walks through the weight-loss-to-sexual-function chain, why Zepbound and Mounjaro are identical for this question, a Zepbound-vs-Wegovy comparison, the PCOS angle where androgen normalization cuts both ways, the transient early-titration dip, why midlife vaginal dryness usually points to menopause, and the oral-contraceptive and pregnancy warning.
Read the analysis→ - Scientific deep-dive10 min · 15 sources
Wegovy and Sex Drive in Women: What the Evidence Shows
Wegovy is the 2.4 mg weight-management dose of semaglutide - the highest routine dose, built for the biggest weight loss - so women ask two opposite things: will it kill my sex drive, or will I want sex more once the weight is gone? No randomized trial has ever measured female sexual desire as an endpoint for Wegovy or any semaglutide dose, so a precise libido number is a guess. What the evidence supports: meaningful weight loss improves female sexual function scores (arousal, lubrication, satisfaction, less painful sex) across randomized lifestyle data and bariatric-surgery meta-analyses, and Wegovy's STEP 1 weight loss (-14.9%) sits in that same range. The women-specific twist is PCOS, where semaglutide lowers elevated androgens and restores ovulation - which can blunt androgen-driven libido in some while raising overall satisfaction in others. This review separates the early-treatment nausea dip, the menopause overlap (vaginal dryness is not a Wegovy effect), and the pregnancy and contraception safety note from the hype on both sides.
Read the analysis→
How we work
Every data point in our investigations is verified directly against provider websites, and the dataset updates continuously. Every scientific deep-dive cites primary literature from PubMed, the FDA, or peer-reviewed clinical trials — never blog summaries or marketing pages. Articles are reviewed and revised whenever the underlying evidence base changes.
We do not sell or recommend specific medical treatments — talk to a licensed clinician before starting any medication. Read our full methodology →